|Articles|March 1, 2014

SLT versus other treatment options

SLT is a popular treatment option for glaucoma. In this article, Dr McAlinden discusses his recent paper that reviewed comparative studies from peer-reviewed journals, finding encouraging and reassuring results about SLT.

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Subscribe

Related Content

Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds

ByOphthalmology Times Europe Staff

July 1st 2026

(Image credit: AdobeStock/Viktor) Study finds similar corneal biomechanics in 2 major glaucoma types

Similarity in corneal biomechanics between 2 major glaucoma types: More alike than expected?

ByOTE Staff Reports

June 12th 2026

EGS 2026: Glaucoma surgery, imaging and neuroscience take centre stage in Brussels

ByOTE Staff Reports

May 29th 2026

First commercial FLIGHT procedures performed as ViaLase begins European launch

BySheryl Stevenson

May 28th 2026

Rethinking SLT: From pressure reduction to biological activation

ByFrancisco Fernando Suñe, MD

May 5th 2026

Latest CME

Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Video

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

SLT versus other treatment options

Related Content

Phaco-GSL outperforms in acute angle-closure glaucoma over chronic cases, 2-year study finds

Similarity in corneal biomechanics between 2 major glaucoma types: More alike than expected?

EGS 2026: Glaucoma surgery, imaging and neuroscience take centre stage in Brussels

First commercial FLIGHT procedures performed as ViaLase begins European launch

Rethinking SLT: From pressure reduction to biological activation

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Treatment Optimization in the Evolving Anti-VEGF Era

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Trending on Eye Care Network - Ophthalmology Times

Retinal imaging as a window into atrial fibrillation

OCT-980 receives FDA orphan drug designation for retinitis pigmentosa

First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP

The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD

Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery